Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy

Trial Profile

Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2007

At a glance

  • Drugs CYT 005 AllQbG10 (Primary)
  • Indications Hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 19 Sep 2007 Status changed from recruiting to completed.
    • 01 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top